MedTrace Logo

Measurement of Circulating Tumor Cells in Prostate Cancer

NCT04101305 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2019-09-24

No results posted yet for this study

Summary

Can tumor cells and tumor DNA be sampled from blood samples from prostate cancer patients? Is it possible to understand the causal relationship between the occurrence of the tumor cells and the tumor DNA in the blood by reviewing the patient's medical records, including information about investigations, analytical reports or diagnoses? Can gene defects that may be useful in predicting the best treatment be detected by sequencing individual tumor cells or plasma from blood samples?

Conditions

  • Prostatic Neoplasms

Interventions

DIAGNOSTIC_TEST

IsoPic

Biomimetic circulating epithelial cell enrichment followed by epithelial cell detection and single cell DNA sampling and sequencing

Sponsors & Collaborators

  • Karolinska Institutet

    collaborator OTHER

  • iCellate Medical

    collaborator INDUSTRY

  • Sormland County Council, Sweden

    lead OTHER

Principal Investigators

  • Evangelos Digkas, MD, PhD · Region Sormland

Eligibility

Min Age
18 Years
Max Age
125 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-30
Primary Completion
2020-12-31
Completion
2021-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04101305 on ClinicalTrials.gov